X4 Pharmaceuticals Statistics Share Statistics X4 Pharmaceuticals has 11.41M
shares outstanding. The number of shares has increased by 1.16%
in one year.
Shares Outstanding 11.41M Shares Change (YoY) 1.16% Shares Change (QoQ) 1.01% Owned by Institutions (%) 0.04% Shares Floating 8.16M Failed to Deliver (FTD) Shares 150 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 2.47M, so 10.99% of the outstanding
shares have been sold short.
Short Interest 2.47M Short % of Shares Out 10.99% Short % of Float 11.03% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -3.94 and the forward
PE ratio is -2.56.
X4 Pharmaceuticals's PEG ratio is
0.06.
PE Ratio -3.94 Forward PE -2.56 PS Ratio 57.69 Forward PS 2 PB Ratio 6.66 P/FCF Ratio -1.12 PEG Ratio 0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.41,
with a Debt / Equity ratio of 3.53.
Current Ratio 3.41 Quick Ratio 3.33 Debt / Equity 3.53 Debt / EBITDA -2.83 Debt / FCF -0.6 Interest Coverage -4.15
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $17.88K Profits Per Employee $-261.89K Employee Count 143 Asset Turnover 0.02 Inventory Turnover 0.28
Taxes Income Tax 310K Effective Tax Rate -0.83%
Stock Price Statistics The stock price has increased by -82.03% in the
last 52 weeks. The beta is 0.61, so X4 Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.61 52-Week Price Change -82.03% 50-Day Moving Average 2.26 200-Day Moving Average 8.44 Relative Strength Index (RSI) 57.99 Average Volume (20 Days) 4,201,719
Income Statement In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M
and earned -37.45M
in profits. Earnings per share was -5.7.
Revenue 2.56M Gross Profit 1.76M Operating Income -36.4M Net Income -37.45M EBITDA -27.58M EBIT -28.37M Earnings Per Share (EPS) -5.7
Full Income Statement Balance Sheet The company has 55.7M in cash and 78.09M in
debt, giving a net cash position of -22.39M.
Cash & Cash Equivalents 55.7M Total Debt 78.09M Net Cash -22.39M Retained Earnings -515.36M Total Assets 105.17M Working Capital 50.05M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -130.9M
and capital expenditures -326K, giving a free cash flow of -131.23M.
Operating Cash Flow -130.9M Capital Expenditures -326K Free Cash Flow -131.23M FCF Per Share -19.58
Full Cash Flow Statement Margins Gross margin is 68.83%, with operating and profit margins of -1423.58% and -1464.61%.
Gross Margin 68.83% Operating Margin -1423.58% Pretax Margin -1452.48% Profit Margin -1464.61% EBITDA Margin -1078.45% EBIT Margin -1423.58% FCF Margin -5132.07%
Dividends & Yields XFOR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for XFOR is $9,
which is 147.3% higher than the current price. The consensus rating is "Buy".
Price Target $9 Price Target Difference 147.3% Analyst Consensus Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 28, 2025. It was a
backward
split with a ratio of 1:30.
Last Split Date Apr 28, 2025 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -9.11 Piotroski F-Score 3
